SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that management will hold an investor conference call on Thursday, August 7, 2008 at 11:00 a.m. ET/8:00 a.m. PT to discuss financial results for the second quarter ended June 30, 2008.
Individual and institutional investors can access the call via (877) 340-7912 (U.S. and Canada) or (719) 325-4871 (international). To access the live audio webcast or the subsequent archived recording, visit the “Investors and Media - Calendar of Events” section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis’ website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin (formerly SNS-595), in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
CONTACT: Investors, Eric Bjerkholt, SVP, Corp. Development & Finance of
Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or Media, Karen L. Bergman,
+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners
for Sunesis Pharmaceuticals, Inc.
Web site: http://www.sunesis.com/
